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Ph-positive chronic myeloid leukemia (CML) and Ph-negative
chronic myeloproliferative diseases (MPDs), characterized in
many cases by the presence of the JAK2V617F mutation, have
many features in common and yet also show fundamental
differences. In this review, we pose five discrete and related
questions relevant to both categories of hematological malig-
nancy, namely: What are the mechanisms that underlie disease
progression from a relatively benign or chronic phase? By what
therapeutic methods might one target residual leukemia stem
cells in CML? Is JAK2V617F the original molecular event in MPD?
What epigenetic events must have a role in dictating disease
phenotype in MPDs? And finally, Will the benefits conferred by
current or future JAK2V617F inhibitors equal or even surpass the
clinical success that has resulted from the use of tyrosine
kinase inhibitors in CML? These and others questions must be
addressed and in some cases should be answered in the
foreseeable future.
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Introduction
Progress in understanding the biology of chronic myeloproli-
ferative diseases (MPDs) continues apace. Although in recent
years there was a tendency to regard Ph-positive chronic
myeloid leukemia (CML) as an entity quite distinct from
Ph-negative myeloproliferative diseases, the categorization
proposed originally by Dameshek in 1951, whereby all the
so-called myeloproliferative diseases (MPDs) form part of a
spectrum with perhaps more similarities than differences,
increasingly proves to be ‘correct’. In this paper, we have
considered very recent developments in five closely related
areas, namely the molecular mechanisms that might underlie
the progression of CML from the chronic phase (CP) to blastic
transformation, some of the approaches that might be useful to
target residual CML stem cells in treated patients on the
assumption that they may have the capacity to regenerate the
complete clinical picture of CML, the question whether
JAK2V617F is the initial molecular event in MPDs, the issue of
what sort of molecular or epigenetic lesions might define the
clinical phenotype in JAK2V617F-positive disorders and finally,
newer approaches to targeting JAK2 in clinical practice. In each
case, there seem to be lessons that could apply equally to both
Ph-positive and Ph-negative diseases.
What causes CML to progress?
Treatment of early CP CML with imatinib (IM) significantly
reduces its rate of progression,1,2 but transformation is still a
major therapeutic challenge as in the majority of those patients
who do progress to blast crisis, the response to tyrosine kinase
inhibitor (TKI) therapy is not durable.3,4 This is often attributed to
the heterogeneous nature of the advanced phase of CML,5 in
which various chromosomal and molecular abnormalities are
usually present, some of which may have a role in maintaining
the transformed state, such as by the inactivation of tumor
suppressor genes.6,7 In the TKI era, the molecular changes
observed comprise deletions, insertions or point mutations
involving various genes, including BCR-ABL1.6,7 Such genetic
lesions including DNA copy number aberrations appear to
occur predominantly in blast crisis, more commonly in
lymphoid than in myeloid crisis; in contrast, genetic lesions
have been identified more rarely in patients with CP or
accelerated-phase CML.6 In most patients with lymphoid blast
crisis, the most frequent mutations occur at CDKN2A/B (50–
67%), whereas in myeloid blast crisis, mutations in the p53
locus occur inB30% of patients, but not a single genetic lesion
has yet been identified at high frequency.5,6,8 However, it is
worth noting that in experimental mice, specific blast crisis-
associated chromosomal translocations (e.g., NUP98-HOXA9)
can transform a BCR-ABL1-induced myeloproliferative-like
phenotype into a blast crisis-like disease.9
Despite the nonrandom nature of some of the cytogenetic
changes observed in advanced-phase CML, it is unlikely that
any specific secondary chromosomal abnormality can directly
cause disease progression. The precise molecular events
predisposing to blastic transformation are also unknown,
although activation of Wnt and Hedgehog signaling and
inhibition of the protein phosphatase 2A (PP2A) may all make
major contributions.10–17
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The molecular changes mentioned above could be secondary
as evidence is now being accumulated to support the concept
that the greatly increased BCR-ABL1 kinase activity in CD34þ
granulocyte-macrophage progenitors (GMPs) could be the
primary determinant of disease progression,5–7 as a series of
epigenetic changes that determine the phenotype of blast crisis
CD34þ /CD38þ /CD45RAþ GMP seems to depend on in-
creased BCR-ABL1 activity.5,18 The differentiation arrest of
GMPs depends on the ability of high BCR-ABL1 activity to
activate mitogen-activated protein kinase (extracellular signal-
regulated kinase 1/2) that, in turn, enhances the translational
inhibitory effect of the RNA-binding protein hnRNP E2 on
C/EBPa, which is the major regulator of myeloid maturation.19
Similarly, the self-renewal ability of GMP results from BCR-
ABL1-independent20 and BCR-ABL1-dependent10,21 signals
leading to the inhibition of GSK 3b (glycogen synthase kinase
3b) and consequently to the activation of b-catenin, and
mutations that generate a mis-spliced and thereby inactive
GSK3b mRNA have been detected in B50% of blast crisis
patients.12 Furthermore, BCR-ABL1 dramatically perturbs the
CML transcriptome resulting in altered expression of genes, of
which some (e.g., PRAME, MZF1, EVI-1, WT1 and JUN-B) might
also have a role in disease progression.6,11,22,23
The post-transcriptional, translational and post-translational
effects of high levels of BCR-ABL1 may also be important. They
may result in the activation of factors with reported mitogenic
and anti-apoptotic activity (e.g., MYC, JAK2, LYN, STAT5,
BMI-1, PI-3K/AKT and BCL-2-related proteins) as well as in the
inhibition of major key regulators of cellular processes, such as
p53 and PP2A.5–7 Indeed, the suppression of PP2A is essential
for the induction and maintenance of BCR-ABL1-generated
oncogenic signals and also allows BCR-ABL1 to be expressed at
high levels.24 These postulated BCR-ABL1 dose-dependent
mechanisms of altered gene regulation, clearly not limited to
those cited above, may explain blastic transformation in CML
patients who do not seem to have any chromosomal or
molecular abnormalities, and may also explain the relative
sensitivity, at least initially, of blast crisis cells to TKIs.
Interestingly, the BCR-ABL1 oncoprotein increases the inci-
dence of point mutations and chromosomal aberrations by
simultaneously inducing pathways that lead to the accumulation
of free radicals causing oxidative damage and altering the
efficiency and faithfulness of the DNA repair machinery.25 In
this regard, the acquisition of resistance to TKI has also been
attributed to the BCR-ABL1-induced genomic instability and
cells presenting with high BCR-ABL1 activity show decreased
sensitivity to IM and frequently develop TKI-resistant mutant
subclones.26,27 As resistance to TKI that was independent of
BCR-ABL1 but dependent on the SRC family member LYN
kinase has also been reported,28 TKI resistance might also be a
factor that facilitates disease progression.
Furthermore, it is quite possible that the genetic instability of
CML blast crisis depends both on an increased propensity of
CML CP progenitors to undergo genetic changes and on the
probability that one of the mutations induced by BCR-ABL1 or
by some other mechanism functions as an ‘amplifier’ of a
genetically unstable phenotype. Indeed, there is also a cohort of
CML patients (B15%) presenting with deletions of the derivative
chromosome 9, whose leukemia may be more prone to genomic
instability ab initio;29 such patients progressed to blast crisis
much more rapidly than CML patients lacking the der9 deletion,
although this may not be the case in the ‘imatinib era’. The same
considerations may apply to the recently described GATA-2
L359V mutation and to the loss of chromosome Y observed in
CML patients who were undergoing blastic transformation.30,31
To date, strong evidence supports the idea that the dosage of
BCR-ABL1 kinase activity has a pivotal role in many CML
patients undergoing progression, and that in some cases
secondary genetic or chromosomal abnormalities can facilitate
transformation, whereas in other cases they just influence the
aggressiveness of the already transformed CML blast crisis
progenitor cell clone. Indeed, B30% (pre-IM era)32,33 and
B50% (post-IM era)34 of blast crisis patients do not show
chromosomal abnormalities and presumably only a fraction of
these patients have molecular inactivation of the p53 gene, yet
their overall survival is only marginally better than that of
patients with chromosomal abnormalities. Thus, the crucial
answered question is, ‘What controls BCR-ABL1 expression and
activity during progression?’ A possible scenario might include a
BCR-ABL1 autoregulatory loop that amplifies signals, which
positively influence BCR-ABL1 gene transcription and enhance
its protein stability by preventing its proteasome-dependent
degradation. Conversely, we cannot exclude the possibility that
there could be a single genetic lesion, still unidentified, that
occurs in CP CML with high frequency and predisposes to
blastic transformation.
Targeting residual leukemia stem cells
Various lines of evidence support the conclusion that leukemia
stem cells (LSCs) are rarely, if ever, eradicated by treatment with
TKIs. Although TKIs induce rapid hematological and cytogenetic
responses in the majority of CP CML patients,1,2 relapse of the
disease is generally observed when TKI treatment is interrupted.
A recent study conducted on 14 CML patients treated with IM
for a minimum of 4 years showed that BCR-ABL1 levels were
maintained in primitive hematopoietic stem cell (HSC) (CD34þ ,
CD38 fraction) despite continuous IM treatment.35 Mathema-
tical models have been used to analyze the in vivo kinetics of
disease response to TKIs in CML patients, providing a
quantitative understanding of the CML cell dynamics with
respect to mutation, selection and genetic instability. These
models support the idea that TKIs are potent inhibitors of the
production of differentiated CML cells, but do not completely
eradicate CML.36
All CP CML patients present with a subpopulation of stem
cells that are quiescent and are characterized by a primitive
phenotype (CD34þ , CD38, HLA DR, CD45RA, CD71),
which are not targeted by TKIs even at high concentrations
(reviewed in the study by Pellicano and Holyoake37). The
presence of such TKI-resistant LSCs could explain the residual
disease in optimally responding patients and the relapse
observed in most patients who discontinue TKIs. The mechan-
ism(s) that allow these cells to be insensitive to TKIs remains
unclear. Although in a few cases the presence of mutations in
the kinase domain of LSCs may explain their drug resistance,
such mutations cannot be detected after exposure to drug in
vitro, and when relapse occurs after TKI discontinuation the
relapse is the usual BCR-ABL1 fusion gene without mutations,38
implying that the relapse in these cases was not due to LSCs with
IM-resistant kinase domain (KD) mutations.
Several new strategies to target CML stem cells are now under
investigation. The principal target of TKIs is proliferating cells;
hence, one possible approach to eradicating primitive quiescent
CML cells would be to stimulate cell cycle entry before or
during treatment with TKIs. In vitro pulsing with growth factors,
such as G-CSF (granulocyte-colony stimulating factor), promotes
cell cycle reentry before and after treatment with IM and
significantly improves stem cell targeting in comparison with IM
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alone.39 Although this particular study provided solid data for a
randomized, multicenter, pilot study to investigate the effect of
G-CSF treatment together with intermittent IM, clinical results
did not show a benefit for either pulsed IM or pulsed IM in
combination with G-CSF.40
Another approach is based on the notion that induction of
autophagy may have a pro-survival effect. If so, the use of
autophagy inhibitors, such as chloroquine, might enhance the
therapeutic effects of TKIs in targeting CML.41 We have shown
that IM treatment in vitro induces autophagy in primary CML
cells, including stem cells. Furthermore, by suppressing autop-
hagy, either by knocking down essential autophagy genes or
with pharmacological inhibitors, it is possible to promote cell
death induced by IM.42
In addition to targeting BCR-ABL1, other areas of research
include investigating drugs that target molecular pathways
commonly defective in cancer. One class of anticancer drugs
that has received much attention is the farnesyl transferase
inhibitors, designed to target the activation of oncogenes,
including RAS. BCR-ABL1 activates the RAS signaling pathway,
which promotes enhanced proliferation and malignant transfor-
mation. A farnesyl transferase inhibitor developed by Bristol-
Myers Squibb, Wallingford, CT, USA (BMS-214662) signifi-
cantly reduces quiescent CML stem cell numbers by the
induction of apoptosis.43 It synergizes with TKIs to overcome
the anti-proliferative effect exerted by these agents on CML stem
and progenitor cells.43 Although BMS-214662 exerts a strong
farnesyl transferase inhibitor activity in vitro, its overall
mechanism of action in killing the LSC fraction is still unclear.
Another drug with a strong potential for targeting quiescent
CML stem cells is the sphingosine analog FTY720, a powerful
activator of the tumor suppressor PP2A.17,44 At the last ASH
meeting, Perrotti’s group reported that SET-dependent suppres-
sion of PP2A activity is a common feature of Ph-positive
progenitors and IM/dasatinib-insensitive CD34þ /CD38 BCR-
ABL1-positive stem cells but not of the equivalent cell fractions
obtained from healthy individuals.45 By clonogenic, colony-
forming cell (CFC)/replating, long term colony-forming cell
(LTC-IC) and carboxyfluorescein succinimidyl ester (CFSE)-
mediated cell division-tracking assays, they showed that
FTY720 (2.5mM) suppresses survival and self-renewal and
triggers apoptosis of BCR-ABL1-positive stem/progenitor cells
isolated from the bone marrow of CML blast crisis patients and/
or from SCL-tTA-BCR-ABL transgenic animals. It must be noted,
FTY720 did not exert any significant effect on the CFSEMAX
quiescent stem cell fraction obtained from healthy individuals.
Perrotti’s group also showed that BCR-ABL1-independent PP2A-
regulated signals control the survival and self-renewal of CML
stem cells through a mechanism that may involve the activation
of b-catenin that may be a PP2A target essential for the self-
renewal of the CML blast crisis GMPs.20
Finally, Pandolfi and colleagues have suggested a new
approach to cancer therapy that targets non-proliferating cancer
stem cells. They showed that when hematopoietic stem cells
derived from mice that lacked the tumor suppressor promyelo-
cytic (PML) leukemia protein are first transduced with BCR-
ABL1 and then transplanted into irradiated recipients, thus
inducing leukemia, the quiescent LSCs rapidly enter cell cycle
which leads to LSC exhaustion.45 As the cells start to proliferate,
they become more sensitive to chemotherapeutic drugs. In their
study, such mice (i.e., PML null LSC) treated with cytarabine
achieved complete remission of leukemia. Interestingly, in the
same study, CML patients with low levels of PML expression had
a good clinical outcome. Therefore, another possible approach
to the elimination of residual LSC could be to target PML.
Is JAK2-V617F the initiating lesion in Ph-negative MPDs?
When the mutated JAK2V617F is expressed in bone marrow cells
by retroviral transduction46–50 or in transgenic mice.51–55 MPD
phenotypes ranging from thrombocytosis to polycythemia and in
some cases myelofibrosis can be observed. These results have
been interpreted as evidence that MPD is initiated by JAK2V617F
as a single-step process. However, several observations suggest
that in patients with MPD, the situation is more complex and
that other mutations may precede the acquisition of
JAK2V617F 54–56 The first surprise was that in many patients with
essential thrombocythemia (ET), but also polycythemia vera (PV)
and primary myelofibrosis (PMF), the JAK2V617F mutation was
present in only a small proportion of cells and could be detected
only by a sensitive real-time PCR assay.57,58 In patients with a
mutant JAK2V617F allele burden ofo25%, the granulocytes that
did not carry JAK2V617F were frequently clonal, as determined
by the X-chromosome inactivation pattern in females or by the
presence of deletions on chromosome 20q.55 These data
suggested that in some MPD patients, somatic mutations in
genes other than JAK2 precede the acquisition of the JAK2V617F
mutation. Similar conclusions were reached by comparing the
relationship between granulocyte clonality and JAK2V617F allelic
ratio.54 A correlation between clonality and the JAK2V617F
allelic ratio was shown for PV but not for ET or PMF.54 The
finding of endogenous erythroid colonies with wild-type JAK2 in
MPD patients with JAK2V617F 56,59 and studies on familial MPD
that showed an inherited predisposition to acquiring somatic
mutations in JAK2V617F60 further strengthened the concept that
genetic alterations may precede JAK2V617F. An analysis of single
colonies obtained from patients positive for JAK2V617F and
del(20q) showed that del(20q) could occur before or after the
acquisition of JAK2V617F 61. Therefore, del(20q) is unlikely to be
a predisposing event for acquiring JAK2V617F
The presence of two different mutations in the same patient
can represent sequential clonal evolution, that is, both muta-
tions are acquired sequentially in the same cell. Alternatively,
the two mutations may represent two independent clones (bi-
clonal disease). Evidence for bi-clonal disease was obtained by
analysis of single colonies in a patient with JAK2V617F (exon 14)
and a JAK2 exon 12 mutation.59 Furthermore, MPD patients
with mutations in the thrombopoietin receptor, MPL, frequently
also carry JAK2V617F. In a larger series, JAK2V617F and MPL
mutations represented bi-clonal disease in all six cases
studied.62 The occurrence of two rare events, such as JAK2V617F
and JAK2 exon 12 mutation or JAK2V617F and MPL-W515K/L, in
two different progenitors from the same patient further supports
the idea that patients with MPD carry a predisposition to
acquiring rare somatic mutations. Such predisposing mutations
could be acquired, affecting blood cells only, or could be
inherited through the germ line. Evidence for the latter model
was obtained by studying X-chromosomal inactivation in single
colonies from female patients with bi-clonal disease.62 Interest-
ingly, several groups recently reported that JAK2V617F mutations
preferentially occur on one of the two chromosomes 9 that carry
a haplotype defined by a series of single-nucleotide polymor-
phisms within the JAK2 gene.63–65 Although this association is
statistically highly significant, the increased risk of acquiring
JAK2V617F in carriers of the 46/1 haplotype (also known as the
CCGG haplotype) is only moderately increased (relative
risk¼ 2.6). It remains to be determined whether the JAK2V617F
mutation preferentially arises on chromosome 9 with the
46/1 haplotype or whether the JAK2V617F mutation on the 46/1
haplotype has a selective advantage and more frequently
initiates MPD.
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Somatic mutations in TET2, a gene of as yet unknown
function, have been detected in B14% of MPD patients and in
B30% of patients with myelodysplastic syndrome, as reported
very recently.66–70 Frame shifts, stop codons or substitutions of
conserved amino acids were detected either as heterozygous or
homozygous mutations. Mutations in TET2 were also observed
in familial cases of MPD, but the mutations in these family
members were acquired and not inherited through the germ
line. TET2 gene mutations could precede the acquisition of
JAK2V617F, but the opposite order of events cannot be excluded.
The detailed report on this very interesting new gene must be
awaited, and a number of questions regarding the role of these
mutations in MPD will have to be addressed in the future.
Novel mechanisms in MPDs
The seminal discovery of the JAK2V617F mutation early in 2005
followed by the description of JAK2 exon 12 and MPL mutations
has facilitated the diagnosis and has also improved the knowl-
edge of the pathogenesis of MPDs, particularly that of
polycythemia vera. However, it was soon recognized that this
mutation, although integral to the myeloproliferative process in
murine models, may not be the sole and even sufficient
molecular event. In the last couple of years, experimental
support has been provided to each of the main four different
theories currently advocated, alone or in combination, to
explain the puzzle of ‘one mutation-different diseases’, that
are: (1) a different stem cell as the target of the mutation; (2)
variable levels of JAK2 kinase activity as a reflection of the
relative proportion of mutated and wild-type protein in cells; (3)
the unique genetic background of the host; and (4) a pre-JAK2
molecular event. These points were critically reviewed by
James71 at the 2008 ASH meeting, and the possible role of pre-
JAK2V617F events, including novel mutations in TET2, a putative
tumor suppressor gene located at 4q24, discovered recently in
Vainchencker’s laboratory,66 is mentioned above. Therefore,
although the search for other genetic defects in patients either
positive or negative for JAK2 and MPL mutations is actively
pursued by adopting high-throughput genomic approaches,
there has been a growing interest in the last couple of years in
the study of ‘post-genomic’ abnormalities that might contribute
to or cause the phenotypic variability of the disorders, including
regulation of genes at the epigenetic level or mediated by
microRNAs, and post-translational protein modification.
Epigenetic abnormalities in cancer cells point to cell-heritable
defects that affect gene expression and occur as a result of two
main mechanisms, namely DNA methylation and modifications
(acetylation or methylation) of histones.72 A large body of
information exists regarding both hypermethylation at specific
gene loci, particularly of tumor suppressor genes, and global
DNA hypomethylation in cancer cells from solid tumors or
hematological neoplasia. However, studies on epigenetics in
MPDs are still scanty, but there is increasing evidence indicating
that some genes, which are supposedly involved in MPD
pathogenesis, can be abnormally regulated at the epigenetic
level. For example, reduced levels of SOCS3, a member of the
family of suppressors of cytokine signaling which function as
negative regulators of the JAK2 signaling pathway, have been
reported in cells obtained from MPD patients, particularly those
with PMF, and have been ascribed to promoter gene hyper-
methylation.73,74 Another example is the SDF1 receptor CXCR4,
which is abnormally downregulated in the CD34þ hemato-
poietic progenitor cells that constitutively circulate in PMF
patients. The reduced transcriptional activity of CXCR4 is caused
by hypermethylation at specific CpG islands of the promoter, that
reverted to normal state after short-term incubation with the
demethylating agent 5-aza-deoxycitidine; furthermore, a signifi-
cant reduction in the proportion of in vitro-generated JAK2V617F
mutated cells was observed after long-term incubation of CD34þ
cells with a combination of 5-azacitidine and an histone
deacetylase (HDAC) inhibitor.75 These treatments also resulted
in the correction of the abnormal in vitro migratory characteristics
of CD34þ cells 76 and in their seeding in the bone marrow of
NOD/SCID mice.77 However, a global methylome profile of
MPD cells is not yet available, and the significance of these
observations still needs to be confirmed. In this regard, it is of
interest that the constitutively increased activation of the JAK–
STAT pathway can promote epigenetic silencing of genes
important for cellular transformation, according to findings that
over-activation of the Hopscotch gene, a JAK homolog gene,
caused a global disruption of heterochromatic gene silencing and
tumor formation in Drosophila melanogaster.78 Thus far, the
question whether targeting epigenetic mechanisms in MPDs is a
useful therapeutic strategy has only been addressed in a few small
clinical trials. 5-Azacitidine was used in patients with refractory/
relapsed PMF and post-polycythemic/post-thrombocythemic MF
in two Phase II trials differing in drug scheduling,79,80 whereas the
preliminary results of a Phase II multicenter study with decitabine
in PMF have also been reported;81 however, only minimal
clinical responses were recorded. On the other hand, a novel
HDAC inhibitor, ITF2357, showed promising clinical activity in a
Phase II trial, particularly in PV and ET patients, accompanied by
evidence of a progressive decline of cells harboring the V617F
allele.82 In vitro, the drug significantly reduced proliferation of
JAK2V617F mutated cells, including endogenous erythroid colony
formation, through the post-transcriptional downregulation of
JAK2.83
Orchestrating gene expression in normal adult cells and
during development is one role of microRNAs (miRNAs), which
is a large family of small non-coding RNAs. However, miRNAs
can also function either as oncogenes or oncosuppressors84 in
human cancer, including acute or chronic leukemias. There are
data indicating that miRNAs may be abnormally regulated in
MPD cells, usually by a general downregulation as reported in
other cancer cells. Conversely, some miRNAs were found to be
overexpressed and this apparently correlated with the JAK2V617F
mutation;85,86 in particular, there are preliminary data suggest-
ing that miRNA-16 can be involved in the abnormal expansion
of erythroid compartment in PV.87 However, we need more
information about miRNA gene targets and the mechanisms
underlying their differential expression in MPDs.
Additional complexity can originate from abnormal post-
translational protein modification, as recently discovered by
Green and colleagues88 who studied deamidation of the anti-
apoptotic protein Bcl-xL, which is known to be upregulated in
both CML and PV. Recent data indicate that a BH3 mimetic
peptide induces apoptosis in JAK2V617F high-allele burden PV
erythroblasts, preventing their proliferation and inhibiting the
generation of endogenous erythroid colonies.89 In normal cells,
Bcl-xL deamidation in response to etoposide or radiation-
induced DNA damage is a mechanism used for deleting
mutated cells through a DNA damage-induced apoptotic
pathway. It was found that induced Bcl-xL deamidation is
prevented in JAK2V617F or BCR-ABL mutated cells; the fact that
incubation of PV or CML myeloid cells with JAK2 inhibitors or
IM, respectively, restored the Bcl-xL deamination pathway,
would support a causal link between the defective deamination
response and the aberrant tyrosine kinase activity. It is tempting
to speculate that the accumulation of clonal cells harboring
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damaged DNA due to the inadequacy of Bcl-xL deamination
might facilitate the stepwise progression of PV or CML to acute
leukemia. Additional support for the role of defective modifica-
tions of key proteins in MPD cells is derived from the
observation that SOCS3 is unable to exert its negative regulation
of JAK/STAT signaling because the turnover of the protein is
reduced, unlike that of SOCS1; in fact, exogenous SOCS3 was
actually found to promote, rather than to reduce, the prolifera-
tion of murine cell lines expressing JAK2V617F possibly as a
consequence of V617F-induced protein hyperphosphoryla-
tion.90
Do JAK2 inhibitors represent the future for MPD therapy?
Ph-negative MPDs: a need for better therapy
The therapy of the Ph chromosome-negative MPDs, namely ET,
PV and PMF, is at an exciting crossroad where on the one hand
there is an explosive increase in our understanding of their
pathogenetic mechanisms and on the other hand there is rapid
evolution of targeted therapies designed to block these
mechanisms. Until now, the treatment of the Ph-negative MPDs
has been by far most effective in the earliest phases of disease.
Specifically, for PV and ET agents such as anagrelide and
hydroxyurea have clearly reduced the risk of both thrombotic
and hemorrhagic events. However, such drugs have not been
very valuable in the later phases of disease, especially for those
patients with late-phase primary myelofibrosis or myelofibrosis
arising after earlier ET or PV (post ET–PV–MF).91 Indeed, current
therapies have been unable to prevent progression to either
these phases or to acute leukemia.91 Allogeneic stem cell
transplantation can cure patients with advanced MPD disorders,
but is still associated with an appreciable risk of short- and long-
term morbidity and mortality; moreover, the increasing average
age of patients with MPDs means that only a minority are really
good candidates for transplantation procedures.
The discovery of several key MPD-associated mutations has
broadened the therapeutic horizons for these disorders signifi-
cantly.92 Starting with the discovery of the JAK2V617F mutation
in exon 14 of JAK2, there are presently 10 mutations described
in JAK2 exon 12. In addition five mutations thus far have been
identified in the thrombopoietin receptor MPL. All of these
mutations seem to feed into a final common pathway of cellular
activation through the PI3 kinase pathway, the STAT pathway
and the mitogen-activated protein kinase pathway.92
Various therapeutic strategies are being developed for
attempting to block the proliferative stimulus associated with
these MPD-associated mutations. Current testing of the thera-
peutic inhibition of these inhibitors can be classified into three
groups, specifically pre-clinical (based on the in vitro activity
against JAK2V617F-containing cells), those with ongoing testing
in murine models and those undergoing testing in clinical trials.
Although there is a pipeline of between 10 and 20 agents with
reported in vitro or murine model activity, we will focus on
those agents in which clinical activity has already been reported
in the public forum. The clinical results JAK2 inhibition can be
divided into three categories of agents. The first comprises novel
small molecules designed and tested for specificity and
selectivity against JAK2 (INCB 018424, XL019, TG101348).
The second comprises agents that inhibit various kinases,
including JAK2 (ITF2357, CEP-701). The third comprises agents
that have previously shown clinical activity in Ph-MPDs in
which their impact on JAK2 (and on JAK2V617F) allele burden is
being measured, such as pegylated interferon a-2.
JAK2 inhibitors for myelofibrosis
The most mature clinical experience for a JAK2 inhibitor is for
INCB018424 (Incyte Co, Wilmington, DE, USA) (selective
against JAK1 and JAK2) with the largest PMF trial in history
(4120 patients). This agent leads to significant reduction in
splenomegaly and dramatic improvement in constitutional
symptoms.93 Although a well-tolerated drug, the suppression
of the JAK–STAT pathway (including normal hematopoiesis
which signals through this pathway) can lead to treatment-
related thrombocytopenia and anemia.92 Additional drugs being
tested are early in their results (TG101348Fselective JAK2
inhibitor (TarGen, San Francisco, CA, USA),94 XL019Fselective
JAK2 inhibitor (Exelexis, San Francisco, CA, USA),95 CEP-701
(TKI of JAK2 and FLT3) (Cephalon, Frazer, PA, USA),96 ITF2357
(histone deacetylase inhibitor) (AQ18Italfarmaco, Italy)97 but
preliminary results also report improvements in splenomegaly
and symptoms in MF patients (Table 1). No JAK2 inhibitor has
yet reported a significant ability to improve cytopenias, fibrosis
or histological changes associated with MF. There is not yet a
clear difference in terms of efficacy between selective and non-
selective JAK2 inhibitors. Pathogenetically, what separates MF
from PV and ET is not yet clear, but is probably not solely the
currently identified JAK2 or MPL mutations. This latter fact could
explain why a JAK2 inhibitor could lead to only a partial
response in MF patients, akin to the more limited ability of IM
mesylate to achieve response in accelerated or blast-phase CML.
JAK2 inhibitors for PV and ET
PV (with 99% of patients having a mutation somewhere in their
JAK2) could well be the most straightforward target of JAK2
inhibition, and preliminary results of trials with XL01998, CEP-
701 (Cephalon),99 and ITF234797 show activity in decreasing
erythrocytosis. However, these trials are too early in their
accrual to allow any useful conclusions as to their efficacy.
Interestingly, in PV, the agent that has shown an ability to lead to
significant reductions in JAK2V617F allele burden in 30–40% of
patients (including complete molecular remissions) is pegylated
interferon-a-2.100
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Table 1 Currently reported efficacy for JAK2 inhibitors from clinical trials in patients with myelofibrosis
Anemia Splenomegaly Constitutional symptoms Pruritus + JAK2 burden Myeloproliferation Reference
INCB018424 o10% X X X 10% X Verstovsek et al.93
CEP-701 o10% X X F Not reported X Verstovsek et al.96
XL019 F X X X 10-20% X Shah et al.95
TG101348 F X X X Not reported X Pardanani et al.94
ITF2357 F X X X 8-12% X Rambaldi et al.97
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Future impact of JAK2 inhibitors
The future of MPDs seems bright because of the level of
excitement and resulting scientific effort directed toward studying
them. The JAK2 inhibitors bring great excitement to the field of
Ph-negative MPDs because of their targeted approach. However,
although this pipeline of agents that inhibit JAK2 is strong, will
any of the agents discussed or in development achieve remissions
or alter the course of MF (or even PV/ET)? Presently, JAK2
inhibitors have provided a valuable and incremental benefit over
existing options particularly for symptoms and quality of life, but
have no impact yet on anemia or more advanced disease
features. Preliminary evidence is encouraging, although it too
early to know the true impact that these agents will have on the
proliferative aspect of the disorders or the risk of disease
progression, and nothing is known about whether these agents
will decrease the thrombotic and hemorrhagic risks, both major
problems in PV and ET. In a changing landscape for Ph-negative
MPDs these new agents, or subsequent generations, may have a
significant role whether this role will entail the use by themselves
or in combination with existing therapies.
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